Kura Oncology (NASDAQ:KURA) Raised to Hold at StockNews.com

Kura Oncology (NASDAQ:KURA - Get Free Report) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a report issued on Thursday.

Several other research firms have also recently weighed in on KURA. JMP Securities reissued a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a research report on Thursday, February 6th. Bank of America decreased their price objective on Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, November 22nd. Scotiabank cut their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. Jefferies Financial Group decreased their target price on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a report on Thursday, November 21st. Finally, BTIG Research cut shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Kura Oncology currently has an average rating of "Moderate Buy" and an average price target of $27.13.

Remove Ads

Kura Oncology Stock Down 6.0 %

KURA stock traded down $0.46 during trading on Thursday, reaching $7.25. 1,403,702 shares of the stock were exchanged, compared to its average volume of 1,613,107. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $6.98 and a twelve month high of $24.17. The firm's 50 day moving average is $8.14 and its 200 day moving average is $13.73. The firm has a market cap of $563.79 million, a P/E ratio of -3.07 and a beta of 0.78.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. As a group, research analysts forecast that Kura Oncology will post -2.44 EPS for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company's stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 over the last 90 days. Corporate insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently added to or reduced their stakes in KURA. Virtus ETF Advisers LLC raised its stake in shares of Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after acquiring an additional 3,061 shares during the last quarter. Harbor Advisors LLC purchased a new position in shares of Kura Oncology in the 4th quarter valued at approximately $87,000. E Fund Management Co. Ltd. bought a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $90,000. Corton Capital Inc. purchased a new stake in Kura Oncology in the fourth quarter worth $99,000. Finally, Optimize Financial Inc bought a new position in Kura Oncology in the fourth quarter worth $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.